Outlook Therapeutics (OTLK) Long-Term Investments (2020 - 2026)
Outlook Therapeutics (OTLK) reported Long-Term Investments of $468430.0 for Q1 2026, down 24.87% year-over-year from $623486.0 in Q1 2025, and down 8.79% quarter-over-quarter from $513549.0 in Q4 2025.
Outlook Therapeutics (OTLK) Long-Term Investments (2020 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 7 years of Long-Term Investments data on file, last reported at $468430.0 in Q1 2026.
- Long-Term Investments for Q1 2026 came in at $468430.0, down 24.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $468430.0 (down 24.87% YoY), and the FY2025 annual result was $552183.0, down 20.34% from the prior year.
- Long-Term Investments eased to $468430.0 in Q1 2026 per OTLK's latest filing, from $513549.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $826435.0 in Q4 2022 and troughed at $468430.0 in Q1 2026.
- A 5-year average of $708662.0 and a median of $765885.0 in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2026: Long-Term Investments surged 74.79% in 2022, then declined 24.87% in 2026.
- A 5-year view of Long-Term Investments shows it stood at $826435.0 in 2022, then declined by 3.62% to $796480.0 in 2023, then declined by 17.15% to $659895.0 in 2024, then fell by 22.18% to $513549.0 in 2025, then declined by 8.79% to $468430.0 in 2026.
- Business Quant data shows OTLK's Long-Term Investments at $468430.0 in Q1 2026, $513549.0 in Q4 2025, and $552183.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | 468,430.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,430.00 |
| Dec 31, 2025 | 513,549.00 |
| Sep 30, 2025 | 552,183.00 |
| Jun 30, 2025 | 592,602.00 |
| Mar 31, 2025 | 623,486.00 |
| Dec 31, 2024 | 659,895.00 |
| Sep 30, 2024 | 693,190.00 |
| Jun 30, 2024 | 708,388.00 |
| Mar 31, 2024 | 765,885.00 |
| Dec 31, 2023 | 796,480.00 |
| Sep 30, 2023 | 793,932.00 |
| Jun 30, 2023 | 802,282.00 |
| Mar 31, 2023 | 809,470.00 |
| Dec 31, 2022 | 826,435.00 |
| Sep 30, 2022 | 804,930.00 |
| Jun 30, 2022 | 812,156.00 |
| Mar 31, 2022 | 823,961.00 |
| Dec 31, 2021 | 830,005.00 |
| Sep 30, 2021 | 853,660.00 |
| Jun 30, 2021 | 464,654.00 |